ECSP13012481A - Composiciones de anticuerpo anti-vegfr-3 - Google Patents

Composiciones de anticuerpo anti-vegfr-3

Info

Publication number
ECSP13012481A
ECSP13012481A ECSP13012481A ECSP13012481A EC SP13012481 A ECSP13012481 A EC SP13012481A EC SP13012481 A ECSP13012481 A EC SP13012481A EC SP13012481 A ECSP13012481 A EC SP13012481A
Authority
EC
Ecuador
Prior art keywords
vegfr
antibody compositions
antibodies
diseases
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Bronislaw Pytowski
Krishnadatt Persaud
Nathalie Zayek
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44584686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012481(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of ECSP13012481A publication Critical patent/ECSP13012481A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a anticuerpos monoclonales anti-VEGFR-3, composiciones farmacéuticas que contienen los anticuerpos y usos de los anticuerpos en el tratamiento de enfermedades.
ECSP13012481 2010-09-07 2013-03-06 Composiciones de anticuerpo anti-vegfr-3 ECSP13012481A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38043210P 2010-09-07 2010-09-07

Publications (1)

Publication Number Publication Date
ECSP13012481A true ECSP13012481A (es) 2015-03-31

Family

ID=44584686

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012481 ECSP13012481A (es) 2010-09-07 2013-03-06 Composiciones de anticuerpo anti-vegfr-3

Country Status (25)

Country Link
US (2) US8481034B2 (es)
EP (1) EP2614081B1 (es)
JP (1) JP2013538813A (es)
KR (1) KR20130042601A (es)
CN (1) CN103080133A (es)
AR (1) AR082641A1 (es)
AU (1) AU2011299443B2 (es)
BR (1) BR112013005423A2 (es)
CA (1) CA2809375C (es)
CL (1) CL2013000607A1 (es)
CO (1) CO6690754A2 (es)
CR (1) CR20130065A (es)
DO (1) DOP2013000039A (es)
EA (1) EA023331B1 (es)
EC (1) ECSP13012481A (es)
ES (1) ES2568801T3 (es)
GT (1) GT201300058A (es)
MA (1) MA34487B1 (es)
MX (1) MX2013002718A (es)
PE (1) PE20131328A1 (es)
SG (1) SG188265A1 (es)
TW (1) TWI413527B (es)
UA (1) UA109148C2 (es)
WO (1) WO2012033696A1 (es)
ZA (1) ZA201300804B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150246118A1 (en) 2012-10-26 2015-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
KR101521981B1 (ko) * 2013-07-31 2015-05-20 가톨릭대학교 산학협력단 혈액암 줄기세포 증식 또는 생착 억제용 조성물
JP6854765B2 (ja) * 2015-01-15 2021-04-07 オンコクエスト ファーマシューティカルズ インコーポレイテッド 標的への抗癌剤の送達を増加させる方法
CN110004167A (zh) * 2019-04-16 2019-07-12 中国医学科学院血液病医院（血液学研究所） 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2435503C (en) * 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US7635760B2 (en) 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies

Also Published As

Publication number Publication date
US8784818B2 (en) 2014-07-22
ES2568801T3 (es) 2016-05-04
AU2011299443A1 (en) 2013-02-14
MX2013002718A (es) 2013-05-01
AU2011299443B2 (en) 2014-06-05
UA109148C2 (uk) 2015-07-27
CA2809375A1 (en) 2012-03-15
US20130280278A1 (en) 2013-10-24
AR082641A1 (es) 2012-12-19
GT201300058A (es) 2014-07-16
ZA201300804B (en) 2014-07-30
KR20130042601A (ko) 2013-04-26
US8481034B2 (en) 2013-07-09
US20120058126A1 (en) 2012-03-08
WO2012033696A1 (en) 2012-03-15
CA2809375C (en) 2016-02-09
CO6690754A2 (es) 2013-06-17
EA023331B1 (ru) 2016-05-31
BR112013005423A2 (pt) 2016-06-07
PE20131328A1 (es) 2013-11-18
TW201223543A (en) 2012-06-16
MA34487B1 (fr) 2013-08-01
CR20130065A (es) 2013-03-21
TWI413527B (zh) 2013-11-01
CL2013000607A1 (es) 2014-04-11
SG188265A1 (en) 2013-04-30
JP2013538813A (ja) 2013-10-17
DOP2013000039A (es) 2013-04-15
EP2614081B1 (en) 2016-03-16
EA201390117A1 (ru) 2013-06-28
CN103080133A (zh) 2013-05-01
EP2614081A1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
CY1119852T1 (el) Σκευασμα αντισωματος και θεραπευτικα σχηματα
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
BR112013028908A2 (pt) anticorpos c-kit e usos dos mesmos
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
CO7081144A2 (es) Anticuerpos biespecíficos contra tweak humana e il17 humana y usos de los mismos
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
ECSP11011387A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
ECSP12011701A (es) Anticuerpos anti-cdcp1 humanizados
EA201400579A1 (ru) Антитела к il-36r
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201401204A1 (ru) Антитела к il-23p19
CL2014001345A1 (es) Metodos de tratamiento usando un anticuerpo contra interferon gamma; usos composicion farmaceutica que contiene un anticuerpo contra interferon gamma.
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
ECSP10010295A (es) Formulacion de anticuerpo
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
GT201200096A (es) Anticuerpos monoclonales
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения